Solventum (NYSE:SOLV) Stock Rating Cut to Hold at Wall Street Zen

Solventum (NYSE:SOLV) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

A number of other brokerages have also recently issued reports on SOLV. Stifel Nicolaus lifted their price objective on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wedbush raised their price target on shares of Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. BTIG Research restated a “buy” rating on shares of Solventum in a research report on Friday. Jefferies Financial Group reissued a “buy” rating on shares of Solventum in a research report on Thursday, October 8th. Finally, Benchmark reiterated a “buy” rating on shares of Solventum in a report on Thursday, October 8th. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $90.27.

Solventum Stock Up 3.6%

Shares of SOLV stock opened at $90.34 on Friday. The company has a 50 day simple moving average of $87.73 and a two-hundred day simple moving average of $78.70. Solventum has a 12 month low of $62.38 and a 12 month high of $94.16. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The stock has a market cap of $15.38 billion, a P/E ratio of 11.94, a P/E/G ratio of 1.24 and a beta of 0.69.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, November 5th. The company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.34 by $0.11. The business had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.93 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.50 earnings per share. On average, research analysts expect that Solventum will post 7.21 earnings per share for the current year.

Institutional Trading of Solventum

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Solventum during the 2nd quarter valued at about $150,066,000. Bank of America Corp DE grew its stake in shares of Solventum by 0.6% in the first quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock worth $93,561,000 after acquiring an additional 9,083 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Solventum in the 2nd quarter worth $61,460,000. Dimensional Fund Advisors LP boosted its position in Solventum by 44.0% during the first quarter. Dimensional Fund Advisors LP now owns 774,683 shares of the company’s stock worth $50,576,000 after acquiring an additional 236,659 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Solventum by 16,656.8% in the third quarter. Assenagon Asset Management S.A. now owns 482,930 shares of the company’s stock valued at $42,570,000 after purchasing an additional 480,048 shares during the period.

Solventum News Roundup

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Solventum earned $1.45 per share on $1.95 billion in revenue, beating consensus estimates of $1.34–$1.35 per share and $1.93 billion in sales. The company raised its 2026 adjusted EPS guidance to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Q3 results
• Positive Sentiment: Analysts lifted price targets: Piper Sandler raised its target to $110 and reaffirmed an overweight rating; Wells Fargo increased its target to $95 while retaining an equal-weight rating. Jefferies raised its target to $98. Piper Sandler rating
• Neutral Sentiment: The company said the 7% year-over-year sales decline (organic sales down 2.8%) reflected, in part, a temporary ERP transition effect: customers had placed advance orders in the prior quarter ahead of the system cutover. Solventum also reported that its separation process was more than 90% complete. Q3 earnings and ERP impact
• Negative Sentiment: Despite the quarterly beat, revenue fell 7% year over year and EPS was down from $1.50 a year ago, highlighting ongoing comparisons and execution risks. Quarterly earnings details

About Solventum

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.